

NEWS RELEASE

FOR IMMEDIATE RELEASE

December 1, 2023

Chiesi Farmaceutici S.p.A. appoints Methapharm as Canadian Distributor for KENGREXAL®

Methapharm is pleased to announce that it has been appointed the Canadian distributor for KENGREXAL (cangrelor). Chiesi acquired the worldwide rights to KENGREXAL from The Medicines Company in 2016, and it was authorized for sale in Canada in January 2023.

About Methapharm Specialty Pharmaceuticals

Methapharm is a privately held specialty pharmaceutical company that focuses on the acquisition, licensing, and promotion of healthcare products in North America. Methapharm markets its own proprietary products as well as partners with global companies in order to deliver a line of products in the USA and Canada.

About Chiesi Farmaceutici S.p.A.

Chiesi is an international group based in Parma, Italy, with over 85 years of experience. The Chiesi Group researches, develops and markets innovative drugs in three specific areas: AIR (products and services in the respiratory field, from infants to adults), RARE (innovative solutions and personalized services to improve the quality of life of patients with rare and ultra-rare diseases) and CARE (products and services to support specialist care, personal care and well-being).

###

For more information about Methapharm or business development inquiries, please contact:

Chris Calenti

Exec. Vice President

Tel: (+1) 519.751.3602 x7222

For more information on KENGREXAL: Please consult the product monographs available on our website at www.methapharm.com for important information relating to adverse reactions, drug interactions, and dosing information. The product monographs are also available by calling us at 1-800-287-7686 ext 7804.

KENGREXAL is a registered trademark of Chiesi Farmaceutici S.p.A.